Treatment of Atypical Glandular Endometrium (Endometrial Hyperplasia with Atypia)
For women NOT desiring fertility, total hysterectomy with bilateral salpingectomy is the definitive treatment due to the 25-40% risk of concurrent endometrial carcinoma. 1, 2
Women Who Do NOT Desire Fertility
Hysterectomy (preferably minimally invasive) with bilateral salpingectomy is the standard of care. 1, 2 This approach:
- Eliminates the substantial risk of concurrent undiagnosed endometrial cancer (present in up to 40% of cases)
- Provides definitive treatment with excellent 5-year survival (93%)
- Removes the need for ongoing surveillance and risk of progression
Key surgical considerations:
- Minimally invasive approach is preferred when technically feasible 1
- Bilateral fallopian tubes must be removed 3
- Ovarian preservation can be considered in younger patients without genetic risk factors 2
- No indication for lymphadenectomy or sentinel lymph node biopsy for hyperplasia with atypia 3
Women Who DESIRE Fertility Preservation
Levonorgestrel-releasing intrauterine system (LNG-IUS) is the most effective fertility-sparing treatment, achieving 88% complete response with only 14% recurrence rate. 4 This represents the highest quality and most recent evidence specifically addressing atypical hyperplasia outcomes.
Mandatory Pre-Treatment Requirements
Before considering conservative management, ALL of the following criteria must be met 2:
Pathology confirmation: Diagnosis must be confirmed by specialist gynecologic pathologist using dilatation and curettage (D&C) - NOT pipelle biopsy, as D&C is superior for accurate grading 2
Imaging exclusion: Pelvic MRI (or expert ultrasound) must exclude:
- Myometrial invasion
- Adnexal involvement
- Suspicious lymph nodes 2
Referral to specialized center: Patients must be managed at centers with expertise in fertility-sparing treatment 2
Informed consent: Patients must understand this is NON-STANDARD treatment with:
Genetic evaluation: Assess for Lynch syndrome and inherited cancer risk 1
Treatment Protocol
Primary treatment options in order of preference:
Oral progestins - Alternative if LNG-IUS not feasible 2
- Medroxyprogesterone acetate (MPA) 400-600 mg/day, OR
- Megestrol acetate (MA) 160-320 mg/day
- 80% complete response rate
- 22% recurrence rate (higher than LNG-IUS) 4
Combination regimens - Consider for enhanced response 4
- Oral progestins + metformin
- LNG-IUS + GnRH analogues
- Up to 95% complete response in limited data
Critical contraindications to progestin therapy: Active breast cancer, recent stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, active smoking 1
Surveillance Protocol During Treatment
Mandatory monitoring schedule:
- Endometrial sampling every 3 months via D&C and imaging 3
- Assessment of response at 6 months with D&C and imaging 2
- Treatment continues until two consecutive negative biopsies 3
- Mean time to complete response: 5.6 months 4
Management based on 6-month response:
- Complete response: Continue treatment until two consecutive negative biopsies, then encourage immediate conception 2
- Partial response with fertility desire: Consider maintenance treatment for additional 6 months 2
- No response: Proceed to hysterectomy 2
- Progression: Immediate hysterectomy 1
Reproductive Outcomes
Among women achieving complete response 4:
- 41% pregnancy rate overall
- 30% live birth rate overall
- 39% live birth rate with assisted reproductive technology
- Pregnancy reduces recurrence risk 2
After achieving complete response: Patients should be referred immediately to fertility clinic and encouraged to conceive without delay, as mean time to recurrence is 33 months 4
Post-Treatment Management
After completion of childbearing or treatment failure:
- Total hysterectomy with bilateral salpingo-oophorectomy is recommended 1, 2
- Long-term surveillance required if hysterectomy declined 3
- Recurrence rate remains 19% overall, with mean recurrence at 33 months 4
Common Pitfalls to Avoid
Using pipelle biopsy instead of D&C - Pipelle is inadequate for accurate diagnosis and may miss concurrent cancer 2
Skipping MRI imaging - Essential to exclude myometrial invasion and concurrent cancer 2
Choosing oral progestins over LNG-IUS - LNG-IUS has superior efficacy and lower recurrence 4, 3
Inadequate surveillance frequency - Must perform endometrial sampling every 3 months, not less frequently 3
Delaying conception after response - Pregnancy should be pursued immediately as recurrence risk increases over time 2, 4
Considering hysteroscopic resection as standard - Despite some favorable reports, evidence is limited, heterogeneous, and does not support routine use 4